文献速递前列腺癌

肿瘤CD276表达对前列腺癌浸润免疫细胞及临床病理特征的影响

Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-06-28

本研究通过转录组和蛋白质组分析鉴定CD276为免疫治疗潜在靶点,体内外实验证实CD276敲低可增强CD8+ T细胞向免疫微环境浸润,前列腺癌样本免疫组化分析进一步确认相同发现,结论认为CD276抑制前列腺癌中CD8+ T细胞的富集。

要点

  • CD276被鉴定为调节免疫微环境的关键分子。
  • CD276敲低增强CD8+ T细胞向免疫微环境浸润。
  • 前列腺癌样本免疫组化分析证实相同发现。

核心结论

  • CD276被发现在前列腺癌中抑制CD8+ T细胞的富集。
  • 因此,CD276抑制剂可能是免疫治疗的潜在靶点。

研究设计与样本

  • 采用转录组和蛋白质组分析鉴定CD276为免疫治疗潜在靶点。
  • 通过体内和体外实验确认其作为免疫治疗效应潜在介质的作用。
  • 对前列腺癌样本进行免疫组化分析。

主要发现

  • 多组学分析提示CD276被鉴定为调节免疫微环境的关键分子。
  • 体内实验显示CD276敲低增强CD8+ T细胞向免疫微环境浸润。
  • 前列腺癌样本免疫组化分析进一步证实相同发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced prostate cancer (PCa) is often resistant to immunotherapy. In this study, we examined the role of CD276 in mediating immunotherapeutic effects through changes in immune cell infiltration. METHODS: Using transcriptomic and proteomic analyses, CD276 was identified as a potential target for immunotherapy. Subsequent in vivo and in vitro experiments confirmed its role as a potential mediator of immunotherapeutic effects. RESULTS: Multi-omic analysis suggested that CD276 was identified as a key molecule regulating the immune microenvironment (IM). In vivo experiments revealed that CD276 knockdown was found to enhance CD8+ T cell infiltration into the IM. Immunohistochemical analysis of PCa samples further confirmed the same findings. CONCLUSION: CD276 was found to inhibit the enrichment of CD8+ T cells in PCa. Thus, CD276 inhibitors may be potential targets for immunotherapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Liu J, Kadier A, Guo Y, et al. Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer. Prostate Cancer Prostatic Dis. 2023. PMID: 37380802. doi:10.1038/s41391-023-00690-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。